-

James Reid Named CEO of Versant Health, a MetLife Company

Industry veteran takes the helm at managed vision care leader

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (“MetLife”), announced today that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1.

“James brings extensive and varied experience in the Group Benefits market to Versant Health,” said Todd Katz, chairman of the Versant Health Board of Directors and executive vice president, Group Benefits at MetLife. “His dedication to delivering for customers, focus on building talent and background in both sales and general management makes him ideally suited to lead Versant to new levels of growth.”

Reid brings more than 30 years of experience in the insurance industry to the role. Most recently, he held both domestic and international leadership roles at MetLife, leading Global Employee Benefits, broadening relationships and fueling growth across the globe through partnerships with multinational corporations and distribution relationships with financial institutions. Earlier in his career, Reid spent over 20 years at Aetna where he had responsibility for P&L, sales, underwriting, product strategy, pricing, operations and consumer distribution across a number of senior leadership roles.

“I am looking forward to leading the strong team at Versant Health,” Reid said. “They have built a tremendous business with strong client relationships and unparalleled products. I am humbled and excited to work with them to continue the growth trajectory.”

Reid will succeed Kirk Rothrock, who is retiring after eight years leading the company. During his time with the company, Rothrock led the consolidation and integration of Superior Vision, Block Vision and Davis Vision to create Versant Health, a leading managed vision care company serving more than 35 million members. He will stay on through March 31 to ensure a smooth transition.

“We’d like to thank Kirk for leading the business over the last eight years and being the architect of its growth and success,” Katz said.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.

About Versant Health

Versant Health, a wholly owned subsidiary of MetLife, is one of the nation’s leading managed vision care companies serving more than 35 million members nationwide. Through our Davis Vision plans and Superior Vision plans, we help members enjoy the wonders of sight through healthy eyes and vision. Providing vision and eye health solutions that range from routine vision benefits to medical management, Versant Health has a unique visibility and scale across the total eye health value chain. As a result, members enjoy a seamless experience with access to one of the broadest provider networks in the industry and an exclusive frame collection. Commercial groups, individuals, third parties, and health plans that serve government-sponsored programs such as Medicaid and Medicare are among our valued customers.

Contacts

MetLife Contact:
Kim Friedman
kfriedman@metlife.com
212-578-5428

MetLife, Inc.

NYSE:MET

Release Versions

Contacts

MetLife Contact:
Kim Friedman
kfriedman@metlife.com
212-578-5428

More News From MetLife, Inc.

MetLife Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has received notice of an unsolicited mini-tender offer by Potemkin Limited (“Potemkin”) to purchase up to 100,000 shares of MetLife, Inc. common stock from MetLife shareholders. The offer is for approximately 0.02 percent of MetLife shares of common stock outstanding as of March 31, 2026. Potemkin’s offer price of $44.20 per share is approximately 41.35 percent lower than the $75.36 closing price of MetLife common sto...

MetLife Investment Management Originates $26 Billion in Private Fixed Income Transactions in 2025

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that it originated approximately $26 billion in private fixed income transactions for clients in 2025, increasing total assets under management on MIM’s private fixed income platform to $144.7 billion as of December 31, 2025.1 MIM’s private fixed income platform comprises private corporate and infrastructure debt, private asset-based fin...

MetLife to Announce First Quarter 2026 Results

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the market closes. The earnings news release, financial supplement and related materials will be posted on MetLife’s Investor Relations webpage at investor.metlife.com. MetLife will hold its first quarter 2026 earnings conference call on Thursday, May 7, 2026, from 9-10 a.m. (ET) via a live webcast. Please click on the following link to register: https://ev...
Back to Newsroom